Cancers (solid tumours)

Tecentriq (atezolizumab)

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

Tecentriq (Atezolizumab) injection is a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. Tecentriq is approved either alone or in combination with targeted therapies/chemotherapies, for adult patients with various forms of metastatic non-small cell lung cancer (NSCLC), PD-L1 positive NSCLC after surgery, extensive-stage small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (HCC), and BRAF V600 mutation-positive unresectable or metastatic melanoma.

In case of any adverse events or safety queries, please contact:

If you have a scientific query related to one of Roche's products, please contact:

M-PK-00001196

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsRoche careersPrivacy StatementLegal Statement